

including biosimilars and interchangeable products, and to discuss the important impact these products have on public health. This includes:

- U.S. Biosimilar Markets and FDA Approval Process;
- Enforcement Activities by FDA and FTC;
- The Benefits of Competition; and
- Improving Stakeholder Engagement: Education and Access.

FDA and FTC also encourage comments from stakeholders and the public relating to steps FDA and FTC can take to facilitate a competitive market for biological products.

III. Participating in the Public Workshop

The FDA Conference Center at the White Oak location is a Federal facility with security procedures and limited seating. Attendance will be free and on a first-come, first-served basis. An agenda for the workshop and any other background materials will be made available 5 days before the workshop at <https://www.fda.gov/drugs/news-events-human-drugs/public-workshop-fda-ftc-workshop-competitive-marketplace-biosimilars-03092020-03092020>. If you need special accommodations because of a disability, please contact Sandra Benton (see **FOR FURTHER INFORMATION CONTACT**) at least 7 days before the workshop.

Registration and Requests for Open Public Workshop Speaker Slots. For those interested in participating as an Open Public Workshop speaker, please register at <https://www.eventbrite.com/e/86931096249> as “In-person Open Public Workshop presenter.” Open Public Workshop registrations are due by February 24, 2020; however, if time is available, you may sign up as an Open Public Workshop speaker the day of the meeting. Time and space are limited and available on a first-come, first-served basis. Open Public Workshop speakers may be assigned no more than 5 minutes for their presentation and will deliver oral testimony only (no accompanying slide deck).

We will do our best to accommodate requests to make public comments. Individuals and organizations with common interests are urged to consolidate or coordinate their presentations and request time for a joint presentation. All requests to make oral presentations must be received by February 24, 2020. No commercial or promotional material will be permitted to be presented or distributed at the public workshop.

In-Person Attendance: For those who would like to attend in person, but who are not participating in the Open Public Workshop, please register at <https://www.eventbrite.com/e/86931096249> as “In-person attendee—no participation.” You may choose not to register; however, seating is limited, and space will be available on a first-come, first-served basis.

Persons attending FDA’s workshops are advised that FDA is not responsible for providing access to electrical outlets.

Streaming Webcast of the Public Workshop: For those unable to attend in person, FDA will provide a live webcast of the workshop. To join the workshop via the webcast, please go to <https://www.fda.gov/drugs/news-events-human-drugs/public-workshop-fda-ftc-workshop-competitive-marketplace-biosimilars-03092020-03092020> for the webcast address. Please register at <https://www.eventbrite.com/e/86931096249> as “online (webcast only).”

Media: Please register at <https://www.eventbrite.com/e/86931096249> as “Media” by March 4, 2020.

Transcripts: Please be advised that when a transcript of the public workshop is available, it will be accessible at <https://www.regulations.gov>. It may be viewed at the Dockets Management Staff (see **ADDRESSES**).

Dated: January 29, 2020.

Lowell J. Schiller,

Principal Associate Commissioner for Policy.

[FR Doc. 2020–02101 Filed 2–3–20; 8:45 am]

BILLING CODE 4164–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Cancer Institute; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of meetings of the Board of Scientific Counselors for Basic Sciences National Cancer Institute.

The meetings will be closed to the public as indicated below in accordance with the provisions set forth in section 552b(c)(6), Title 5 U.S.C., as amended for the review, discussion, and evaluation of individual intramural programs and projects conducted by the National Cancer Institute, including consideration of personnel qualifications and performance, and the competence of individual investigators, the disclosure of which would

constitute a clearly unwarranted invasion of personal privacy.

Name of Committee: Board of Scientific Counselors for Basic Sciences; National Cancer Institute.

Date: March 9, 2020.

Time: 9:00 a.m. to 4:30 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: National Institutes of Health, Porter Neuroscience Research Center, 35 Convent Drive, Building 35A, Bethesda, MD 20892.

Contact Person: Mehrdad M. Tondravi, Ph.D., Chief Institute Review Office, NCI, National Institutes of Health, 9609 Medical Center Drive, ROOM 2W–464 MSC 9711, Rockville, MD 20852, 240–276–5664, tondravim@mail.nih.gov.

Name of Committee: Board of Scientific Counselors for Clinical Sciences and Epidemiology; National Cancer Institute.

Date: March 10, 2020.

Time: 9:00 a.m. to 2:30 p.m.

Agenda: To review and evaluate personnel qualifications and performance, and competence of individual investigators.

Place: National Institutes of Health, Porter Neuroscience Research Center, 35 Convent Drive, Building 35A, Bethesda, MD 20892.

Contact Person: Brian E. Wojcik, Ph.D., Institute Review Office, Office of The Director, National Cancer Institute, 6116 Executive Blvd., Room 2201, Bethesda, MD 20892, 301–496–7628, wojcikb@mail.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS)

Dated: January 29, 2020.

Melanie J. Pantoja,

Program Analyst, Office of Federal Advisory Committee Policy.

[FR Doc. 2020–02068 Filed 2–3–20; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

National Library of Medicine; Notice of Closed Meetings

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended, notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable materials,